ALX2004

ALX2004 is a novel, potential best-in-class antibody-drug conjugate (ADC) developed by ALX Oncology for the treatment of solid tumors that express epidermal growth factor receptor (EGFR). The drug is engineered with an affinity-tuned anti-EGFR antibody backbone, a proprietary highly stable linker, and a topoisomerase I inhibitor payload designed to maximize targeted delivery of chemotherapy to tumor cells while minimizing systemic toxicity. Preclinical studies have demonstrated potent antitumor activity across various EGFR-expressing tumor models without significant EGFR-related skin toxicity or interstitial lung disease at clinically relevant doses. The ADC leverages an enhanced bystander effect and improved stability compared to other ADCs. Phase 1 clinical trials are set to begin in mid-2025 for patients with relapsed/refractory EGFR-expressing solid tumors, including non-small cell lung cancer, colorectal cancer, head and neck squamous cell carcinoma, and esophageal squamous cell carcinoma[1][2][5][6][8][9].